HENDERSON MICHAEL THOMAS 4

What Happened

• Michael Thomas Henderson, a director of Spyre Therapeutics, sold 20,000 shares of SYRE common stock in an open‑market transaction on June 22, 2026. The shares were sold at $100.00 per share for total proceeds of $2,000,000. This was a sale (transaction code S), not a purchase.

Key Details

• Transaction date: 2026-06-22; filing date: 2026-06-23 (filed timely).
• Price per share: $100.00; total value: $2,000,000.
• Shares owned after transaction: not specified in the provided filing summary.
• Footnote: Transaction executed pursuant to a Rule 10b5-1 trading plan adopted February 6, 2026.
• Filing status: timely (no late filing indicated).

Context

• This is a sale executed under a pre-established 10b5-1 plan, which typically means the trade followed instructions set up in advance and may not reflect the insider’s current view of the company. Sales are common and can be for many personal reasons; purchases generally carry more immediate signaling value for investors.